Navigation Links
Immtech Announces Sale of Property Subsidiary in China
Date:1/16/2009

NEW YORK, Jan. 16 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced that the Company has entered into an agreement to sell Immtech Life Science Limited, a subsidiary of the Company which owns land use rights and property in Shenzhen, China, to a third party. Under the agreement, the total purchase price for Immtech Life Science is $2 million in cash. The Company received 30% of the total purchase price following the signing of the agreement, and the buyer shall provide the remaining funds by March 19, 2009.

"The sale of Immtech Life Science represents an important step in our ongoing efforts to ensure that we will have the resources to further develop targeted businesses that could generate revenues in the near term. These businesses include drug development and clinical work and other healthcare related services," said Eric L. Sorkin, Chairman and CEO of Immtech.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global opportunities in the healthcare sector and opportunities in China. Immtech aims to leverage its established expertise and other assets in both new drug sales and enhanced healthcare-related services, including research and information-providing services, for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
4. Immtech Investor Conference Call Scheduled for February 22, 2008
5. Immtech Announces Update on Business Operations
6. Immtech Announces Results From Hepatitis C Discovery Program
7. Immtech Reports Fiscal Year End 2008 Results
8. Immtech Investor Conference Call Scheduled for June 25, 2008
9. Immtech Reports Fiscal Second Quarter 2009 Results
10. Immtech Receives Listing Notice From NYSE Alternext US
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... paper on Crystallization in Process Chemistry by Applying Simple PAT Tools . ... organic compounds to isolate and purify the desired product. Chemists now spend ...
(Date:1/23/2017)... ... ... is a set of camera tools that allow video editors to integrate up to two ... Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video editors can ... ProRandom works by using a virtual camera to create the illusion of a shaky camera. ...
(Date:1/23/2017)... ... 2017 , ... Gynecology Associates of Gwinnett (GAoG) has become ... for women of all ages. The staff of Gynecology Associates of Gwinnett is ... routine health screenings to diagnosing and treating female concerns including menopause, urinary incontinence ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources ... benefits of a seafood-rich diet. These resources have been developed for use ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and ... who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is ... $25 free. Or, spend $200 and get $50 free. , “A lot of people ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)...  ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B ... qu,ils se sont mis d,accord sur le règlement mondial ... et 3B seront autorisés à vendre leurs produits existants ... ResMed effectuera le paiement de la décision en une ... Floride entre les deux parties. Le règlement n,inclut pas ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
(Date:1/23/2017)... Jan 23, 2017 InDex Pharmaceuticals Holding AB ... the 12th congress of the European Crohn,s and Colitis Organisation (ECCO). ... a specific focus on inflammatory bowel disease (IBD). The congress is ... 2017. ... are pleased to again having been selected to present data at ...
Breaking Medicine Technology: